Inspired by nature...
We develop novel products in areas of high unmet health needs, to deliver treatments and relieve suffering for longer, healthier lives.
Share price (delayed 20 mins)
Jul 30 2010
8.38p (+0.00%)
London - PYM
Latest news
- Appointment of Chief Executive Officer 21 June 2010
- USA regulatory approval to begin Phase II clinical trial of Cogane™ 14 June 2010
- Interim Results HY 2010 24 May 2010
The potential Cogane effect in damaged neurons
This animation shows the neurite outgrowth in neurons
